Loading annual review details
Neogen Corporation (NEOG)FY2026 investor yearly review
Across FY2026, management reframed the year as operational stabilization with a heavy focus on cost right-sizing, sample collection efficiency, and the PetriFilm manufacturing transition. As those execution levers improved, food-safety core growth and EBITDA margins strengthened, while animal-safety results were more supply-driven. By Q4, leadership shifted the narrative toward customer-facing offense, higher innovation funding, and targeted operational value leakage reduction.
Overall investor read
Execution improving; still credibility-sensitive
Management’s transformation themes gained traction through Q2–Q4, but guidance framing and ongoing supplier/supply-chain issues keep execution risk visible.
Primary financial signal
FY2026 FCF improved; margins under pressure
Reported profitability remained weak, yet operating cash flow and free cash flow improved, aligning with management’s focus on cash conversion and inventory/supply-chain actions.
Primary call signal
Food-safety offense plan moves center stage
By Q4, management emphasized share-gain targeting, solutions-based selling, and increased R&D to fund growth while continuing efficiency programs.
Headline financial outcomes and balance/cash signals for FY2026.
Revenue
FY revenue declined -2.7% amid execution headwinds.
Gross margin
Gross margin held around mid-40s despite tariff and sample issues.
Operating margin
Operating margin stayed negative, reflecting cost pressures and execution costs.
Net income
Loss widened versus prior year base, despite cash improvements.
Diluted EPS
EPS remained negative; turnaround progress showed more in cash flow.
Free cash flow
Free cash flow improved strongly year-over-year on working-capital and CapEx.
Operating cash flow
Operating cash flow rose to $83.2M as cash conversion improved.
Net cash
Net cash of $185.5M and liquidity supported transformation investments.
FY2026 evolved from CEO-led stabilization to a more offense-oriented, food-safety-led growth plan as operational execution improved and supply issues became more bounded.
Commercial execution
In Q1, management framed execution challenges as the reason food-safety performance didn’t reflect the portfolio’s potential. By Q2 and especially Q3, management pointed to process discipline and commercial excellence, and by Q4 reported stronger food-safety core growth and share-gain positioning through solutions-based selling.
Quarter-by-quarter materiality and tone for annual transcript themes.
Scroll horizontally to see more columns.
| Theme | Q1 | Q2 | Q3 | Q4 | Next monitor |
|---|---|---|---|---|---|
| Food-safety core growth turned into a sustained narrative | Mixed Food safety modest growth; PetriFilm decline clouded execution | Positive |
Management’s repeatable positives were process discipline, food-safety commercial focus, and cash conversion support from inventory and CapEx normalization; the persistent pressure points were margin leakage from sample collection, and quarters where animal-safety supply disruptions or macro/tariff noise resurfaced.
Management linked the improved ability to forecast and raise guidance to a shift from monthly forecasting to a weekly latest-best-estimate process focused on targeted accounts, risks/opportunities, and enabling sales execution.
Across the year, management described multi-quarter improvement efforts, including reducing scrap and backorders. By Q4, sample collection margin losses narrowed to the year’s lowest point, indicating fewer leakage drivers.
FY2026 started with CEO-led stabilization and cash/margin headwinds, improved sequentially through cost actions and sample-collection focus, then finished with food-safety offense and animal-safety supply normalization.
Mixed profitability, improving cash conversion
Product breakdown bars are scaled against the largest annual revenue item; labels show revenue, YoY change, and revenue share.
Regional breakdown bars are scaled against the largest annual revenue item; labels show revenue, YoY change, and revenue share.
FY2026 progressed from cost and process stabilization (including SNOP, inventory and sample collection fixes) to improved food-safety core growth and margin discipline, then toward FY2027 offense anchored on commercial restructuring and expanded R&D.
Management entered the year focused on top-line growth, cost right-sizing, reinvigorating innovation, and deleveraging. Q1 showed mixed segment results: Food Safety growth offset by PetriFilm distributor-related decline, while sample collection inefficiencies and tariff impacts pressured margins and cash.
Read earnings transcriptManagement reported return to positive core growth and sequential adjusted EBITDA margin expansion, attributing benefits to cost structure savings and ongoing sample collection progress. The company raised FY2026 guidance, while maintaining cautious framing around macro weakness and lingering end-market uncertainty.
Management’s FY2026 guidance was raised during the year; transcripts provide directional support for conservatism in guidance construction, but full reconciliation is limited to available disclosed ranges and provided actuals.
Reaffirmed full-year guidance after Q1 met expectations.
Revenue $870.4M; Gross margin 46.9%; Other 3.7%
Q1 management reaffirmed full-year guidance but emphasized multi-quarter margin and cash improvement drivers, limiting clear apples-to-apples scoring from transcripts.
FY2026 revenue raised to $845M–$855M.; Adjusted EBITDA approximately $175M.
Revenue $870.4M; Gross margin 46.9%; Other not_available
Management’s Q2 over-delivery supported a guidance raise, but final adjusted EBITDA actual was not provided in the supplied financial context for scoring.
Forward-looking monitoring points derived from repeated transcript themes, including what management repeatedly tied to future credibility and performance.
Sample collection remained a recurring margin and cash gate for profitability trajectory.
Whether sequential improvements in sample collection scrap, labor efficiency, and gross margin losses persist beyond Q4 lows.
Petrifilm manufacturing control underpinned future innovation capacity and longer-term margin objectives.
First validated SKU completion, multi-quarter transition start in November 2026, and inventory/write-off impact during ramp.
Operational execution
Early in FY2026, management emphasized production testing and inventory/supply-chain improvements while targeting a multi-quarter transition. Q2 advanced production testing and validation for SKUs; Q3 highlighted validation progress and schedule confidence; Q4 reinforced de-risking with full validation milestones and planned in-sourced transitions.
Margin quality
Sample collection inefficiencies and scrap/quality-cost drivers were identified as persistent margin and cash headwinds in Q1 and Q2, with management describing multi-quarter improvement. Q2 guided toward profitability in the second half; Q3 acknowledged uneven progress and supplier quality issues; Q4 described sample collection margin losses narrowing to the year’s lowest point.
Supply chain risk
Throughout FY2026, management repeatedly distinguished animal-safety softness as supply-side disruptions rather than demand collapse. Q2 discussed cautious animal-safety guidance amid macro and production herd uncertainty; Q3 described third-party supplier challenges affecting reported results and prompted a stronger supplier qualification approach; Q4 reported resolution of the majority of global supply issues.
Positive core growth returned; solutions-based selling emphasized
Positive Food Safety milestone: above-market growth target reinforced |
Positive Food safety hit 5.8% core growth; offense posture |
| Watch Food Safety core growth momentum, on-time delivery, and funnel KPIs (funnel size/wins) in 1Q/Investor Day updates. |
| PetriFilm production transfer de-risking became central | Positive PetriFilm production testing started; timeline and in-house expertise stressed | Positive Production testing and product validation advanced for 17 SKUs | Positive Completed validation of equipment; 17 SKUs validation underway | Positive First SKU near full validation; multi-quarter transition begins | Monitor Petrifilm validation milestones (first SKU fully validated), November 2026 transition cadence, and reported sample write-offs tied to readiness. |
| Sample collection inefficiency constrained margins and cash | Negative Elevated sample collection inefficiencies and write-offs pressured gross margin | Mixed Backorder progress improved; profitability expected in 2H despite write-offs | Mixed Supplier quality issue worsened sample collection gross margin outlook | Positive Sample collection margin losses hit lowest point of year | Track sample collection gross margin progress, inventory write-downs, and management’s sequential improvement commentary on execution steps. |
| Cost right-sizing and operational discipline drove EBITDA inflection | Neutral Headcount reduction and SNOP focus aimed to protect cash | Positive Cost actions attributed to sequential EBITDA margin expansion | Positive Cost discipline showed in EBITDA margin despite revenue impact | Positive Operational rigor and value-leakage reduction framed as funding innovation | Watch adjusted EBITDA trajectory versus seasonality, operating expense discipline, and stated value leakage areas: inventory, PVAR, sample margins. |
| Animal safety supplier disruptions reshaped quarterly variability | Negative Cautious animal safety stance amid uncertain back-half evidence | Negative Third-party supplier issues hit Animal Safety results meaningfully | Positive Major supply headwinds resolved; Animal Safety core growth recovered | Monitor supplier qualification outcomes, backorder stability, and Animal Safety core growth excluding supply disruptions commentary in 1Q/2Q. |
| Innovation and R&D ramp shifted from pipeline talk to funded commitments | Neutral R&D pipeline reinvigoration and fewer high-impact projects discussed | Positive Petrifilm innovation line and high-impact innovation framework expanded | Positive R&D investment +50% planned; licensing and analytics upgrades | Track R&D spending ramp, innovation project throughput (Petrifilm SKUs), and whether technology solutions expand customer utilization without margin drag. |
Management repeatedly used equipment validation, SKU validation progress, and the first fully validated SKU milestone to derisk the in-house transition and support longer-term margin expectations.
Management highlighted cash flow benefit from improved trade working capital and lower CapEx. FY2026 free cash flow ended positive, aligning with transformation focus on cash generation.
Animal Safety results were repeatedly described as impacted by third-party supplier issues and documentation/raw material shortages. Even with progress in Q4, management acknowledged challenges continued into Q4 and required supplier qualification reinforcement.
Despite improvement efforts, Q3 noted a negative sample collection gross margin due to a quality issue at a third-party supplier, requiring additional focus to regain steady-state profitability.
Management cited tariff impacts flowing out of inventory and later noted freight/transportation cost increases. These were discussed as meaningful contributors to gross margin and EBITDA variability.
Management emphasized conservative guidance given a brand-new team settling in, and focused on investor credibility and consistency. The narrative implies execution proof still mattered during the year.
Scroll horizontally to see more columns.
| Quarter | Revenue | YoY revenue growth | Diluted EPS | Gross margin | Investor read |
|---|---|---|---|---|---|
| Q1Aug-25 | $209.19M | -7.2% | $0.17 | 45.4% | Management highlighted stabilization actions—cost right-sizing, SNOP, and sample collection improvements—while PetriFilm distributor inventory normalization and tariff effects drove mixed segment results and negative FCF. |
| Q2Nov-25 | $224.69M | 7.4% | $-0.07 | 47.5% | Management tied a sequential EBITDA margin improvement to cost structure savings and advancing sample collection efficiency, while reporting return to positive core growth and updating raised full-year guidance. |
| Q3Feb-26 | $211.2M | -6.0% | $-0.08 | 46.9% | Management delivered solid Food Safety core growth and strong EBITDA margin via cost discipline, but framed Animal Safety weakness as third-party supplier disruptions with a more rigorous supplier qualification response. |
| Q4May-26 | $225.3M | 6.7% | $-0.05 | 47.8% | Management described restored momentum: Food Safety core growth reached a high since 2023 and Animal Safety supply issues were mostly resolved, while innovation investment and operational efficiency plans funded FY2027. |
Food Safety delivered solid core growth with adjusted EBITDA margins reaching 22.8% through cost discipline, while Animal Safety results reflected third-party supplier challenges. Management responded by tightening supplier qualification and kept a more conservative view for Q4 given the evolving headwinds.
Read earnings transcriptManagement closed FY2026 with improving core growth across both units, reporting Food Safety core growth at 5.8% in Q4 and that most Animal Safety supply issues were resolved. The narrative shifted to FY2027 offense: solutions-based selling, strategic accounts, and a funded R&D ramp.
Read earnings transcriptFY2026 revenue raised to $857M–$860M.; Adjusted EBITDA guidance maintained at $175M for fiscal year 2026.
Revenue $870.4M; Gross margin 46.9%; Other not_available
Q3 guidance update reflected stronger-than-expected performance and cautious macro assumptions, but lack of adjusted EBITDA actual prevents full scorecard comparison.
Not available
Revenue $870.4M; Gross margin 46.9%; Other $31.9M
In Q4, management emphasized FY2027 planning rather than incremental FY2026 metric ranges; available transcript guidance doesn’t map cleanly to FY2026 actuals.
Animal safety quarterly variability was driven by third-party supply disruptions, affecting forecast confidence.
Backorder stability, supplier qualification outcomes, and management commentary on whether Q4 improvements sustain.
The year-end shift to offense depended on solutions-based selling and targeted account execution.
Funnel building/wins metrics, on-time/full delivery trends, and early results from strategic account and e-commerce initiatives.
Management planned a material R&D increase to fund innovation and future revenue growth cadence.
Whether R&D scaling translates into validated SKU pipeline throughput and technology solutions that expand markets.
Dafinchi